Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$401.4K (10 inflow days, 10 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 67.5% of shares outstanding.
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BlackRock | Mutual Fund | 2026/Q3 | +463,624 | 1.1% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +25,761 | 0.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +100,148 | 0.2% |
| Man Investment Partners (US) LP | Mutual Fund | 2026/Q3 | +10,662 | 0.0% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +9,109 | 0.0% |
| The Morningside Group Limited | VC/PE Fund | 2026/Q3 | +7,228,337 | 17.4% |
| Alpha Wave Global, LP | Hedge Fund | 2026/Q3 | +7,054,956 | 16.9% |
| Lawrence Miller | Individual/Insider | 2026/Q3 | +459,092 | 1.1% |
| Dennis Molnar | Individual/Insider | 2026/Q3 | +58,014 | 0.1% |
| Paul Sekhri | Individual/Insider | 2026/Q3 | +12,500 | 0.0% |
| Columbia Management Investment Advisers, LLC | Mutual Fund | 2026/Q3 | +7,476,992 | 18.0% |
| Shionogi & Co., Ltd. | Public Company | 2026/Q3 | +4,181,278 | 10.0% |
| Tao Capital Partners | VC/PE Fund | 2026/Q3 | +2,178,138 | 5.2% |
Institutional buy/sell activity by reporting period, largest moves first.
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2 Aug 2026 | Lawrence Miller | Founder & Vice Chair of the Board | Sale to Issuer | -448,247 | – | – |
| 2 Aug 2026 | Lawrence Miller | Founder & Vice Chair of the Board | Other Acquisition | +448,247 | – | 459,092 |
| 2 Aug 2026 | Lawrence Miller | Founder & Vice Chair of the Board | Derivative Sale to Issuer | -2,249,171 | – | – |
| 2 Aug 2026 | Lawrence Miller | Founder & Vice Chair of the Board | Other Derivative Acquisition | +2,249,171 | $8.88 | 74,128 |
| 2 Aug 2026 | Lawrence Miller | Founder & Vice Chair of the Board | Derivative Exercise and Retained | +10,845 | – | 459,092 |
| 2 Aug 2026 | Dennis Molnar | President | Sale to Issuer | -58,014 | – | – |
| 2 Aug 2026 | Dennis Molnar | President | Other Acquisition | +58,014 | – | 58,014 |
| 2 Aug 2026 | Dennis Molnar | President | Derivative Sale to Issuer | -691,732 | – | – |
| 2 Aug 2026 | Dennis Molnar | President | Other Derivative Acquisition | +37,064 | $4.87 | 37,064 |
| 2 Aug 2026 | Dennis Molnar | President | Other Derivative Acquisition | +654,668 | $16.00 | 55,596 |
| 2 Aug 2026 | The Morningside Group Limited | Other Acquisition | +6,915,837 | – | 7,228,337 | |
| 2 Aug 2026 | The Morningside Group Limited | Private Acquisition | +312,500 | $16.00 | 7,228,337 | |
| 2 Aug 2026 | The Morningside Group Limited | Derivative Exercise and Sale | -6,915,837 | – | – | |
| 2 Aug 2026 | Paul Sekhri | Independent Chairperson | Private Acquisition | +12,500 | $16.00 | 12,500 |
| 2 Aug 2026 | Paul Sekhri | Independent Chairperson | Derivative Sale to Issuer | -191,706 | – | – |
| 2 Aug 2026 | Paul Sekhri | Independent Chairperson | Other Derivative Acquisition | +347,264 | $16.00 | 22,238 |
| 2 Aug 2026 | Gary Sender | Independent Director | Derivative Sale to Issuer | -140,844 | – | – |
| 2 Aug 2026 | Gary Sender | Independent Director | Other Derivative Acquisition | +140,844 | $16.00 | 44,477 |
| 2 Aug 2026 | William Jones | Independent Director | Derivative Sale to Issuer | -44,477 | – | – |
| 2 Aug 2026 | William Jones | Independent Director | Other Derivative Acquisition | +44,477 | $16.00 | 44,477 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 879,684 | 2.1% | 3.2 |
| 31 Aug 2026 | 564,832 | 1.4% | 1.5 |
| 14 Aug 2026 | 407,565 | 1.1% | 1.0 |
| 31 Jul 2026 | 0 | 0.0% | 0.0 |
No comments yet — be the first to weigh in on APMD.